Matt Fagan is a counsel in the Life Sciences group at Goodwin. He started at the firm in 2022. Matt represents clients in the medical device and computing technology spaces, holistically protecting hardware and software innovations with patents, copyrights, and trade secrets. He also provides strategic IP portfolio management, counseling related to patent and copyright infringement, and competitive landscape analyses.
In addition to his billable work, Matt has represented pro bono clients through the Volunteer Lawyers for the Arts and the Texas Volunteer Legal Services COVID-19 Eviction Task Force. In his spare time, he works to close the gender gap in computer science; he teaches STEM in his community with Girls who Code and the Girl Scouts of Southwest Texas.
Matt is admitted to practice in Massachusetts and Texas only; his practice is supervised by DC-admitted lawyers at Goodwin.
The legal landscape governing AI in medical devices and life sciences is shifting rapidly. From the FDA's evolving framework for AI-enabled medical software and the EU AI Act's high-risk classification regime, to landmark AI inventorship rulings, generative AI copyright disputes, and new data privacy laws, medtech companies face a higher-stakes IP environment than ever. Join us for a deep dive into the IP and legal strategies that matter most for AI- and data-driven medtech. This session will give you the practical tools and updated frameworks you need to protect your innovations and stay ahead of the law.